Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2018-003640-23Phase 2Terminated
Phase 2, open-label, single-arm trial of velpatasvir in hepatitis C virus infection, sponsored by UPMC ISMETT. Primary endpoint: Absence of HCV infection at 12 weeks after treatment completion. Started Jan 2021; status: terminated.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on 2018-003640-23.